Protein degradation: a validated therapeutic strategy with exciting prospects
- 2 October 2017
- journal article
- review article
- Published by Portland Press Ltd. in Essays in Biochemistry
- Vol. 61 (5), 517-527
- https://doi.org/10.1042/ebc20170030
Abstract
In a time of unprecedented challenges in developing potent, selective and well-tolerated protein inhibitors as therapeutics, drug hunters are increasingly seeking alternative modalities to modulate pharmacological targets. Selective inhibitors are achievable for only a fraction of the proteome, and are not guaranteed to elicit the desired response in patients, especially when pursuing targets identified through genetic knockdown. Targeted protein degradation holds the potential to expand the range of proteins that can be effectively modulated. Drugs inducing protein degradation through misfolding or by modulating cereblon (CRBN) substrate recognition are already approved for treatment of cancer patients. The last decade has seen the development of proteolysis targeting chimeras (PROTACs), small molecules that elicit proteasomal degradation by causing protein polyubiquitination. These have been used to degrade a range of disease-relevant proteins in cells, and some show promising efficacy in preclinical animal models, although their clinical efficacy and tolerability is yet to be proven. This review introduces current strategies for protein degradation with an emphasis on PROTACs and the role of click chemistry in PROTAC research through the formation of libraries of preclicked PROTACs or in-cell click-formed PROTACs (CLIPTACs).Keywords
This publication has 37 references indexed in Scilit:
- Inhibitor Mediated Protein DegradationCell Chemical Biology, 2012
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomideLeukemia, 2012
- Principles of early drug discoveryBritish Journal of Pharmacology, 2011
- Will the Ubiquitin System Furnish as Many Drug Targets as Protein Kinases?Cell, 2010
- Targeting the Undruggable Proteome: The Small Molecules of My DreamsCell Chemical Biology, 2010
- HaloTag: A Novel Protein Labeling Technology for Cell Imaging and Protein AnalysisACS Chemical Biology, 2008
- The Challenge of Drugging Undruggable Targets in Cancer: Lessons Learned from Targeting BCL-2 Family MembersClinical Cancer Research, 2007
- Recognizing and exploiting differences between RNAi and small-molecule inhibitorsNature Chemical Biology, 2007
- The influence of drug-like concepts on decision-making in medicinal chemistryNature Reviews Drug Discovery, 2007
- Structural Basis for an Unexpected Mode of SERM-Mediated ER AntagonismMolecular Cell, 2005